DE:03AF ETF Price & Analysis
03AF ETF Chart & Stats
€43.59
--
Market closed
€43.59
--
Day’s Range― - ―
52-Week Range€35.13 - €44.56
Previous Close€43.59
VolumeN/A
Average Volume (3M)N/A
AUM191.37M
NAV53.79
Expense Ratio0.50%
Holdings Count102
Beta0.87
Inception DateDec 31, 2014
Next Dividend Ex-DateN/A
Dividend Yield
(―)Shares OutstandingN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
AlphaN/A
ETF Overview
ALPS Medical Breakthroughs ETF
The ALPS Medical Breakthroughs ETF (SBIO) is an innovative investment vehicle designed for those looking to capitalize on the dynamic and rapidly evolving biotechnology sector within the broader health care category. This ETF uniquely focuses on small to mid-cap biotechnology companies that are poised at the forefront of medical advancements, particularly those engaged in the development of groundbreaking treatments and therapies. By targeting firms with drugs in Phase II and Phase III clinical trials, SBIO offers exposure to companies on the cusp of delivering potentially transformative health care solutions.
Investors interested in the cutting-edge of medical innovation will appreciate SBIO's strategic approach, which combines focused sector expertise with the potential for high growth. As the global demand for advanced medical treatments continues to rise, this ETF provides a curated portfolio that taps into the heart of scientific discovery and medical progress. With the ALPS Medical Breakthroughs ETF, investors are not just buying into stocks; they are investing in the future of health care and the promise of revolutionary therapies that could redefine medical treatment paradigms.
ALPS Medical Breakthroughs ETF (03AF) Fund Flow Chart
ALPS Medical Breakthroughs ETF (03AF) 1 year Net Flows: €73M
03AF ETF News
03AF ETF FAQ
What was DE:03AF’s price range in the past 12 months?
DE:03AF lowest ETF price was €35.13 and its highest was €44.56 in the past 12 months.
What is the AUM of DE:03AF?
As of Oct 12, 2026 The AUM of DE:03AF is 191.37M.
Is DE:03AF overvalued?
According to Wall Street analysts DE:03AF’s price is currently Undervalued.
Does DE:03AF pay dividends?
DE:03AF does not currently pay dividends.
How many shares outstanding does DE:03AF have?
Currently, no data Available
Which hedge fund is a major shareholder of DE:03AF?
Currently, no hedge funds are holding shares in DE:03AF
03AF ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
CG Oncology, Inc.
3.80%
Oruka Therapeutics, Inc.
3.62%
Veradermics, Incorporated
3.47%
Travere Therapeutics, Inc.
3.33%
Definium Therapeutics, Inc.
3.21%
Dianthus Therapeutics, Inc.
3.10%
Edgewise Therapeutics, Inc.
2.84%
Relay Therapeutics Inc
2.68%
Ideaya Biosciences
2.36%
Xenon Pharmaceuticals
2.36%
Total30.77%
See All Holdings







